McKesson (MCK)
(Delayed Data from NYSE)
$589.99 USD
+4.25 (0.73%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $590.28 +0.29 (0.05%) 6:24 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$589.99 USD
+4.25 (0.73%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $590.28 +0.29 (0.05%) 6:24 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
Here's Why You Should Add McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co
by Zacks Equity Research
Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
5 Solid Dividend Growth Stocks for Thanksgiving
by Sweta Killa
Archer-Daniels-Midland (ADM), McKesson (MCK), ParkerHannifin (PH), Booz Allen Hamilton (BAH) and Darden Restaurants (DRI) could be compelling picks for your portfolio this Thanksgiving.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Here's Why You Should Hold on to Abiomed (ABMD) Stock Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merit Medical's (MMSI) New Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.
Buy These 5 Corporate Giants Flying High in Disappointing 2022
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.
SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEO
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEO
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Cardinal Health's (CAH) Velocare to Enhance at-Home Care
by Zacks Equity Research
Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.